Erica D Warlick

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    Erica D Warlick
    Blood and Marrow Transplant Program, Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:30-8. 2009
  2. ncbi Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions
    Erica D Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota, USA
    Curr Opin Oncol 22:150-4. 2010
  3. ncbi Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas
    Erica D Warlick
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 17:1025-32. 2011
  4. ncbi Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Leuk Lymphoma 52:2045-9. 2011
  5. ncbi Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Res 35:757-61. 2011
  6. ncbi Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation
    Erica D Warlick
    Bone Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota
    Biol Blood Marrow Transplant 18:480-6. 2012

Detail Information

Publications6

  1. ncbi Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    Erica D Warlick
    Blood and Marrow Transplant Program, Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:30-8. 2009
    ....
  2. ncbi Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions
    Erica D Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota, USA
    Curr Opin Oncol 22:150-4. 2010
    ..This review highlights strategies to optimize transplant for MDS and identifies unresolved questions...
  3. ncbi Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas
    Erica D Warlick
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 17:1025-32. 2011
    ....
  4. ncbi Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Leuk Lymphoma 52:2045-9. 2011
    ..We review the current literature regarding natural killer (NK) cell, T cell, and myeloid derived suppressor cell abnormalities in the spectrum of MDS...
  5. ncbi Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Res 35:757-61. 2011
    ..Our data suggest that exposure to consolidation chemotherapy prior to RIC HCT may not improve post-transplant outcomes for patients with AML in CR1...
  6. ncbi Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation
    Erica D Warlick
    Bone Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota
    Biol Blood Marrow Transplant 18:480-6. 2012
    ..The lower DLI dose regimen improved the tolerability of this therapeutic approach, with modest rates of severe aGVHD...